Retatrutide, a experimental dual agonist of the GLP-1 receptor and glucose-dependent insulinotropic polypeptide (GIP) target, is showing promising outcomes in early human studies. Recent research https://shopretatrutidepeptide.com/retatrutide-research-knowledge-hub/